Clonal hematopoiesis confers an increased mortality risk in orthotopic heart transplant recipients

Am J Transplant. 2022 Dec;22(12):3078-3086. doi: 10.1111/ajt.17172. Epub 2022 Aug 26.

Abstract

Novel risk stratification and non-invasive surveillance methods are needed in orthotopic heart transplant (OHT) to reduce morbidity and mortality post-transplant. Clonal hematopoiesis (CH) refers to the acquisition of specific gene mutations in hematopoietic stem cells linked to enhanced inflammation and worse cardiovascular outcomes. The purpose of this study was to investigate the association between CH and OHT. Blood samples were collected from 127 OHT recipients. Error-corrected sequencing was used to detect CH-associated mutations. We evaluated the association between CH and acute cellular rejection, CMV infection, cardiac allograft vasculopathy (CAV), malignancies, and survival. CH mutations were detected in 26 (20.5%) patients, mostly in DNMT3A, ASXL1, and TET2. Patients with CH showed a higher frequency of CAV grade 2 or 3 (0% vs. 18%, p < .001). Moreover, a higher mortality rate was observed in patients with CH (11 [42%] vs. 15 [15%], p = .008) with an adjusted hazard ratio of 2.9 (95% CI, 1.4-6.3; p = .003). CH was not associated with acute cellular rejection, CMV infection or malignancies. The prevalence of CH in OHT recipients is higher than previously reported for the general population of the same age group, with an associated higher prevalence of CAV and mortality.

Keywords: basic (laboratory) research/science; biomarker; clinical research/practice; genomics; heart transplantation/cardiology; molecular biology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clonal Hematopoiesis / genetics
  • Cytomegalovirus Infections*
  • Graft Rejection / epidemiology
  • Heart
  • Heart Transplantation*
  • Hematopoiesis
  • Humans